A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis

Inclusion Criteria:

• Male or female participant aged 18 to 70 years(inclusive)at the time of informedconsent.

• Diagnosis of plaque psoriasis for at least 6 months prior to the screening visit.

≥10% of BSA involvement at screening visit and randomization;

• Psoriasis Area and Severity Index (PASI) score ≥12 and static Physician's GlobalAssessment (sPGA) ≥3 at screening visit and randomization

Exclusion Criteria:

• Participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate,inverse, pustular,or drug induced psoriasis.)

• Has uncontrolled arterial hypertension characterized by a systolic blood pressure (BP) ≥160 mm Hg or diastolic BP ≥100 mm Hg Note: Determined by 2 consecutiveelevated readings. If an initial BP reading exceeds this limit, the BP may berepeated once after the subject has rested sitting for ≥10 minutes. If the repeatvalue is less than the criterion limits, the second value may be accepted

• Class III or IV congestive heart failure by New York Heart Association Criteria

• Participant with a history of chronic bacterial infections (e.g., chronicpyelonephritis, chronic bronchiectasis, or chronic osteomyelitis).